ZHENDE MEDICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.56 CNY | +1.76% |
|
+4.98% | -7.92% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach -100% by 2026.
- The company's profit outlook over the next few years is a strong asset.
- The company's attractive earnings multiples are brought to light by a P/E ratio at 12.46 for the current year.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -7.92% | 813M | - | ||
| -29.70% | 3.15B | B- | ||
| -15.57% | 2.57B | C+ | ||
| +21.75% | 2.55B | - | A- | |
| +7.04% | 2.09B | B | ||
| -1.13% | 2.04B | - | ||
| -0.56% | 1.53B | B | ||
| +0.84% | 1.33B | - | ||
| +23.78% | 1.23B | C | ||
| +4.72% | 1.16B | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 603301 Stock
- Ratings Zhende Medical Co., Ltd.